» Articles » PMID: 38001775

The Contribution of Hippocampal All-Trans Retinoic Acid (ATRA) Deficiency to Alzheimer's Disease: A Narrative Overview of ATRA-Dependent Gene Expression in Post-Mortem Hippocampal Tissue

Overview
Date 2023 Nov 25
PMID 38001775
Authors
Affiliations
Soon will be listed here.
Abstract

There is accumulating evidence that vitamin A (VA) deficiency contributes to the pathogenesis and progression of Alzheimer's disease (AD). All- retinoic acid (ATRA), a metabolite of VA in the brain, serves distinct roles in the human hippocampus. Agonists of retinoic acid receptors (RAR), including ATRA, promote activation of the non-amyloidogenic pathway by enhancing expression of α-secretases, providing a mechanistic basis for delaying/preventing amyloid beta (Aβ) toxicity. However, whether ATRA is actually deficient in the hippocampi of patients with AD is not clear. Here, using a publicly available human transcriptomic dataset, we evaluated the extent to which ATRA-sensitive genes are dysregulated in hippocampal tissue from post-mortem AD brains, relative to age-matched controls. Consistent with ATRA deficiency, we found significant dysregulation of many ATRA-sensitive genes and significant upregulation of RAR co-repressors, supporting the idea of transcriptional repression of ATRA-mediated signaling. Consistent with oxidative stress and neuroinflammation, Nrf2 and NfkB transcripts were upregulated, respectively. Interestingly, transcriptional targets of Nrf2 were not upregulated, accompanied by upregulation of several histone deacetylases. Overall, our investigation of ATRA-sensitive genes in the human hippocampus bolsters the scientific premise of ATRA depletion in AD and that epigenetic factors should be considered and addressed as part of VA supplementation.

Citing Articles

Key target genes related to anti-breast cancer activity of ATRA: A network pharmacology, molecular docking and experimental investigation.

Manoochehri H, Farrokhnia M, Sheykhhasan M, Mahaki H, Tanzadehpanah H Heliyon. 2024; 10(14):e34300.

PMID: 39108872 PMC: 11301165. DOI: 10.1016/j.heliyon.2024.e34300.


Beneficial Effects of -Derived Bioactive Compounds in the Epigenetic Program of Neurodevelopment.

Russo C, Valle M, DAngeli F, Surdo S, Giunta S, Barbera A Nutrients. 2024; 16(14).

PMID: 39064669 PMC: 11280255. DOI: 10.3390/nu16142225.

References
1.
Cuadrado A, Manda G, Hassan A, Alcaraz M, Barbas C, Daiber A . Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach. Pharmacol Rev. 2018; 70(2):348-383. DOI: 10.1124/pr.117.014753. View

2.
Strosznajder A, Wojtowicz S, Jezyna M, Sun G, Strosznajder J . Recent Insights on the Role of PPAR-β/δ in Neuroinflammation and Neurodegeneration, and Its Potential Target for Therapy. Neuromolecular Med. 2020; 23(1):86-98. PMC: 7929960. DOI: 10.1007/s12017-020-08629-9. View

3.
Martin P, Delmotte M, Formstecher P, Lefebvre P . PLZF is a negative regulator of retinoic acid receptor transcriptional activity. Nucl Recept. 2003; 1(1):6. PMC: 212040. DOI: 10.1186/1478-1336-1-6. View

4.
Li J, Park E, Zhong L, Chen L . Homeostatic synaptic plasticity as a metaplasticity mechanism - a molecular and cellular perspective. Curr Opin Neurobiol. 2018; 54:44-53. PMC: 6361678. DOI: 10.1016/j.conb.2018.08.010. View

5.
Manczak M, Kandimalla R, Fry D, Sesaki H, Reddy P . Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease. Hum Mol Genet. 2016; 25(23):5148-5166. PMC: 6078633. DOI: 10.1093/hmg/ddw330. View